Compare Accenture plc (ACN) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Accenture plc vs Quest Diagnostics Inc — how do they compare? Accenture plc trades at $137.69 (market cap $86.98B), while Quest Diagnostics Inc trades at $208.21 (market cap $23.51B). The key difference: Accenture plc is far larger — about 3.7× Quest Diagnostics Inc's market cap, and Accenture plc pays the higher dividend (4.59%). Which is the better fit depends on your goals.
| ACN | DGX | |
|---|---|---|
Market Cap | $86.98B | $23.51B |
Sector | Technology | Health |
52-Week High | $303.33 | $216.02 |
52-Week Low | $124.41 | $166.42 |
Enterprise Value | $85.20B | $29.52B |
Dividend Yield | 4.59% | 1.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Accenture (ACN) trades at $137.19, up 0.17% on the day, with a bearish technical signal from moving averages. The company shows solid fundamentals with a P/E of 11.35, net income margin of 10.66%, and consistent earnings beats in recent quarters. Recent news highlights strategic AI partnerships with TEPCO Solution Advance and AlphaSense, reinforcing its focus on digital transformation services. Operating cash flow strengthened to $11.47 billion in 2025, supporting dividend payments and growth initiatives.
The outlook for ACN is positive, driven by strong analyst sentiment with a consensus price target of $193.92 and 66% buy ratings. Key opportunities include revenue growth from AI adoption and global consulting demand. Risks involve competitive pressures, macroeconomic sensitivity, and execution challenges in integrating new technologies. The stock offers value with reasonable valuation multiples and a track record of profitability.
Quest Diagnostics (DGX) trades at $212.38, down 1.55% today but remains near its 52-week high. The stock shows strong fundamental performance with three consecutive quarterly earnings beats and revenue growth to $11.04 billion in 2025. Technical indicators suggest a bullish trend with support at $212 and resistance at $216. Recent positive developments include New York State approval for the Haystack MRD cancer test, expanding market reach.
DGX presents a balanced investment case with solid fundamentals and analyst support, though valuation appears full. The consensus price target of $222.80 offers modest upside. Key risks include healthcare reimbursement pressures and elevated debt levels. Earnings growth and diagnostic service expansion remain primary catalysts for continued performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Accenture plc
Accenture PLC provides management and technology consulting services and solutions. The Company delivers a range of specialized capabilities and solutions to clients across all industries on a worldwide basis. Accenture operates a network of businesses provides consulting, technology, outsourcing, and alliances.
Read more on ACN →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
